AmgenvsCaris Life Sciences

AMGN and CAI stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$457.93

Value $247B

-0.95%
AMGN's page

CAI

Caris Life Sciences, Inc.

$19.94

Value $5.6B

-5.05%
CAI's page

Amgen (AMGN) has a market value of $247B and Caris Life Sciences (CAI) $5.6B. Over the last year, with dividends, AMGN moved +39.7% and CAI -16.4%. The P/E is 26.3 for AMGN and 58.7 for CAI. Dividend yield: AMGN 2.17%, CAI none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$247B

    CAI$5.6B

    AMGN is 44 times CAI

  • Revenue, 12 months

    AMGN$38.9B

    CAI$1.0B

    AMGN is 37 times CAI

  • Net income, 12 months

    AMGN$9.4B

    CAI$96M

    AMGN is 98 times CAI

  • Operating margin

    AMGN32.4%

    CAI13.4%

    19.0 points apart

  • ROIC

    AMGN16.2%

    CAI11.5%

    4.7 points apart

  • P/E

    AMGN26.3

    CAI58.7

    CAI is 2.2 times AMGN

  • Dividend yield

    AMGN2.2%

    CAI0.0%

    2.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+39.7%

CAI-16.4%

75100125DecFebAprJunAugOct
Returns by period
PeriodAMGNWith dividendsCAIWith dividends
1 year since November 14, 2025+39.7%Price +36.0%-16.4%Price -16.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenCAICaris Life Sciences

Valuation

AMGNCAI
Valuation
Price$457.93$19.94
Market value$247B$5.6B
Enterprise value (EV)$288B–
P/E26.358.7
P/E, 5-year median23.0–
P/B17.28.8
EV/EBIT22.8–
Free cash flow yield3.9%0.5%

Results and growth

AMGNCAI
Results and growth
Revenue, 12 months$38.9B$1.0B
Net income, 12 months$9.4B$96M
Free cash flow, 12 months$9.6B$29M
Earnings per share, 12 months$17.25$0.34
Revenue growth, year on year10.0%97.0%
Revenue growth a year, past+7.6%over 5 years+62.9%over 2 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNCAI
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%13.4%
Net margin24.1%9.2%
ROIC16.2%11.5%
ROE87.8%16.7%

Balance sheet

AMGNCAI
Balance sheet
Cash$13.2B–
Total debt$54.0B–
Net debt / EBITDA2.3–
Interest cover4.8×3.3×

Dividends and buybacks

AMGNCAI
Dividends and buybacks
Dividend yield2.2%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield–0.0%
Shareholder yield2.2%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or CAI

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Caris Life Sciences?

By market value, Amgen ($247B) is about 43.8 times Caris Life Sciences ($5.6B), at today's prices.

How did AMGN and CAI stock do over the last 1 years?

Since November 14, 2025, AMGN's price moved +36.0% and CAI's -16.4%. With dividends: AMGN +39.7% (+39.7% a year), CAI -16.4% (-16.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or CAI?

The dividend yield at today's price is 2.17% for Amgen and none for Caris Life Sciences. Over the last twelve months they paid $9.94 and – per share.

What is the P/E of AMGN and CAI?

At today's price, the P/E is 26.3 for AMGN and 58.7 for CAI. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Amgen or Caris Life Sciences?

Over the last twelve months, the net margin was 24.1% for Amgen and 9.2% for Caris Life Sciences, and the operating margin 32.4% and 13.4%. Revenue was $38.9B and $1.0B.

Which is the better investment, Amgen or Caris Life Sciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.